Technical Data
Ezh2 (Enhancer of Zeste Homolog 2, Polycomb group (PcG) Protein, ENX-1, EZH1, MGC9169)
EZH2, also known as ENX-1, is ubiquitously expressed during early embryo genesis, and becomes restricted to the central and peripheral nervous systems and sites of fetal hematopoiesis during later development. In the adult, EZH2 is restricted to the spleen, testis and placenta. The human EZH2 gene was originally mapped to chromosome 212, but further studies showed that this is a pseudogene, and that EZH2 actually maps to chromosome 7q35 within the critical region for malignant myeloid disorders.
EZH2 and BMI-1 genes are co-expressed in Reed-Sternberg cells of Hodgkin’s disease. Co-expression of BMI-1 and EZH2 is also associated with cycling cells and degree of malignancy in B-cell non-Hogkin’s lymphoma. EZH2 is involved in the progression of prostate cancer, and is also a marker that distinguishes prostate cancers at risk of lethal progression from indolent prostate cancer. EZH2 has been identified as a marker of aggressive breast cancer and a promoter of neoplastic transformation of breast epithelial cell.

Suitable for use in Immunohistochemistry. Other applications have not been tested.

Recommended Dilution:
Immunohistochemistry: 1:50-1:200. Formalin-fixed paraffin-embedded or frozen tissue sections. Requires HIER using citrate Buffer, pH 6.0. Enzyme digestion not required.
Optimal dilutions to be determined by the researcher

Positive Control:
Breast cancer

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
250ul-20°CBlue IceHumanRabbit
Synthetic peptide of human EZH2. Cellular Localization: mainly nuclear.
Purified from rabbit antisera.
Supplied as a liquid in PBS, pH 7.4, 1% BSA, 0.09% sodium azide.
Recognizes human EZH2.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Hobert, O., et al., Mol. Cell Biol. 16: 3066-3073 (1996). 2. Chen, H., et al., Genomics 38: 30-37 (1996). 3. Sewalt, R.G., et al., Mol. Cell Biol. 18: 3586-3595 (1998). 4. van Lohuizen, M., et al., Mol. Cell Biol. 18: 3572-3579 (1998). 5. Cardoso, C., et al., Eur. J. Hum. Genet. 8: 174-180 (2000). 6. Raaphorst, F.M., et al., Am. J. Pathol. 157: 709-715 (2000). 7. van Kemenade, F.J., et al., Blood 97: 3896-3901 (2001). 8. Sellers, W.R., et al., Cancer Cell 2: 349-350 (2002). 9. Varambally, S., et al., Nature 419: 624-629 (2002). 10. Kleer, C.G., et al., PNAS 100: 11,606-11,611 (2003).